On 17/11/22 teplizumab was approved by the US Food and Drug Administration (FDA) as the first ever treatment indicated to delay the onset of stage 3 type 1 diabetes. This is the biggest treatment breakthrough for the condition since the discovery of insulin 100 years ago.
Although teplizumab is not approved in the UK yet, the US approval paves the way for this life-changing treatment to be made available to people at high risk of developing type 1 diabetes in the UK too.
Listen to this Podcast
Find out more
- First ever treatment to delay type 1 diabetes is licensed in the us – Diabetes UK
- Game-changing type 1 diabetes drug approved in US – BBC
- TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D – proventionbio
- Why teplizumab could herald a new era for type-1 diabetes – The Economist